0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessHighlights•Off-target ILDR synergizes with anti-PD-L1 to eradicate non-irradiated tumors•The abscopal effects of ILDR depend on dosimetry (≥1 and ≤3 Gy) and volume•Gut composition governs the abscopal effects of ILDR combined with anti-PD-L1•ILDR and Christensenellaceae influence the emigration of intestinal mregDC to TdLNSummaryThe mechanisms governing the abscopal effects of local radiotherapy in cancer patients remain an open conundrum. Here, we show that off-target intestinal low-dose irradiation (ILDR) increases the clinical benefits of immune checkpoint inhibitors or chemotherapy in eight retrospective cohorts of cancer patients and in tumor-bearing mice. The abscopal effects of ILDR depend on dosimetry (≥1 and ≤3 Gy) and on the metabolic and immune host-microbiota interaction at baseline allowing CD8+ T cell activation without exhaustion. Various strains of Christensenella minuta selectively boost the anti-cancer efficacy of ILDR and PD-L1 blockade, allowing emigration of intestinal PD-L1-expressing dendritic cells to tumor-draining lymph nodes. An interventional phase 2 study provides the proof-of-concept that ILDR can circumvent resistance to first- or second-line immunotherapy in cancer patients. Prospective clinical trials are warranted to define optimal dosimetry and indications for ILDR to maximize its therapeutic potential.Graphical abstract
Jianzhou Chen, Antonin Lévy, Ai-Ling Tian, Xuehan Huang, Guoxin Cai, Marine Fidelle, Conrad Rauber, Pierre Ly, Eugénie Pizzato, Lisa Sitterlé, Gianmarco Piccinno, Peng Liu, Sylvère Durand, Misha Mao, Liwei Zhao, Valerio Iebba, Hannah Felchle, Anne-Laure Mallard de La Varende, Julius C. Fischer, Simon Thomas, Tim F. Greten, Jennifer Jones, Cecilia Monge, Sandra Demaria, Silvia C. Formenti, Lorenzo Belluomini, V. Dionisi, Christophe Massard, Pierre‐Yves Blanchard, Charlotte Robert, Clément Quevrin, Eloise Lopes, Céline Clémenson, Michele Mondini, Lydia Meziani, Yizhou Zhan, Chengbing Zeng, Qingxin Cai, Daphné Morel, Roger Sun, Pierre-Antoine Laurent, Monica Mangoni, Vanessa Di Cataldo, C. Arilli, Maike Trommer, Simone Wegen, Sebastian Neppl, Rachel P. Riechelmann, Marcos Pedro Guedes Camandaroba, Elson Santos Neto, Pierre‐Edouard Fournier, Nicola Segata, Peter Holíček, Lorenzo Galluzzi, Aitziber Buqué, Carolina Alves Costa Silva, Lisa Derosa, Guido Guido Kroemer, Chuangzhen Chen, Laurence Zitvogel, Éric Deutsch (2025). Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. , 43(3), DOI: https://doi.org/10.1016/j.ccell.2025.02.010.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2025
Authors
61
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.ccell.2025.02.010
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
